RNAZ Earnings Transcode Therapeutics, Inc.
Reported diluted EPS by fiscal period (SEC EDGAR). Chart & overview →
1–20 of 20
| Q1 2026 | 2026-03-31 | -21.28 | 2026-05-15 | 10-Q |
| FY 2025 | 2025-12-31 | -52.59 | 2026-04-15 | 10-K |
| Q3 2025 | 2025-09-30 | -34.49 | 2025-11-14 | 10-Q |
| Q2 2025 | 2025-06-30 | -32.45 | 2025-08-14 | 10-Q |
| Q1 2026 | 2025-03-31 | -70.16 | 2026-05-15 | 10-Q |
| FY 2025 | 2024-12-31 | -1336.63 | 2026-04-15 | 10-K |
| Q3 2025 | 2024-09-30 | -1117.89 | 2025-11-14 | 10-Q |
| Q2 2025 | 2024-06-30 | -1290.94 | 2025-08-14 | 10-Q |
| Q1 2025 | 2024-03-31 | -21.35 | 2025-05-14 | 10-Q |
| FY 2024 | 2023-12-31 | -3419.01 | 2025-04-15 | 10-K |
| Q3 2024 | 2023-09-30 | -273.66 | 2024-11-14 | 10-Q |
| Q2 2024 | 2023-06-30 | -373.15 | 2024-08-14 | 10-Q |
| Q3 2023 | 2023-03-31 | -259.07 | 2024-05-15 | 10-Q |
| FY 2023 | 2022-12-31 | -1082.79 | 2024-04-01 | 10-K |
| Q3 2023 | 2022-09-30 | -19.16 | 2023-11-14 | 10-Q |
| Q2 2023 | 2022-06-30 | -12.55 | 2023-08-14 | 10-Q |
| Q1 2023 | 2022-03-31 | -0.27 | 2023-05-15 | 10-Q |
| FY 2022 | 2021-12-31 | -0.81 | 2023-03-31 | 10-K |
| Q3 2022 | 2021-09-30 | -0.58 | 2022-11-14 | 10-Q |
| Q2 2022 | 2021-06-30 | -0.37 | 2022-08-15 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Informational only — not financial advice.